Stockreport

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

Werewolf Therapeutics, Inc.  (HOWL) 
PDF WATERTOWN, Mass., April 04, 2024 (GLOBE NEWSWIRE) --  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company [Read more]